Benzinga | Jun 4, 2021 02:06PM EDT

Tandem Diabetes Care Announces Presentations Demonstrating 'Immediate And Sustained Real-World Improvements With Control-IQ Technology'

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, announced data presented this week on real-world use of the t:slim X2(tm) insulin pump with Control-IQ(tm) advanced hybrid closed-loop technology at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD). Several presentations detailed positive outcomes, including a plenary session today by Boris Kovatchev, PhD, Director of the Center for Diabetes Technology at the University of Virginia, which demonstrated immediate and sustained improvements in time in range (TIR) in more than 9,000 people with diabetes who wore the system for 12 months.

"Experience matters in automated insulin dosing systems, and Control-IQ technology is performing as well in the real world as it did in the pivotal studies," said Dr. Jordan Pinsker, Medical Director at Tandem Diabetes Care. "Additionally, patient-reported outcomes, including reduced diabetes burden and improved sleep quality, demonstrate that our Control-IQ technology can make a positive and sustained impact on the lives of people with diabetes."